AbbVie submits Rinvoq for ankylosing spondylitis
In a pivotal Phase II/III study, twice as many patients receiving the drug achieved the primary endpoint of ASAS 40 response at week 14 versus placebo
Read More
Tag: upadacitinib
AbbVie’s Rinvoq hits targets in atopic dermatitis trial
The JAK inhibitor significantly improved skin clearance and reduced itch
Read More
AbbVie’s Rinvoq shows potential for atopic dermatitis
The selective and reversible JAK inhibitor hit all goals in the Phase III Measure Up study
Read More
AbbVie files Rinvoq for psoriatic arthritis
Rinvoq is a selective and reversible JAK inhibitor being studied in several immune-mediated inflammatory diseases
Read More
Rinvoq bags FDA green light
In the SELECT programme, the oral JAK inhibitor met all primary and ranked secondary endpoints across a variety of rheumatoid arthritis patients.
Read More
Positive late stage rheumatoid arthritis trial results for Abbvie
Upadacitinib was found to have achieved both primary endpoints with significantly higher rates of ACR20 response and low disease activity at week 14.
Read More
First PhIII trial of AbbVie’s upadacitinib a success
AbbVie’s experimental drug upadacitinib has hit primary and secondary targets in the first late-stage trial of the drug involving patients with moderate-to-severe rheumatoid arthritis (RA).
Read More
- King’s Doctoral Training Centre to investigate MS symptom management
- Agenda announced for FlyPharma Vienna 2024
- Therapy reprogrammes immune cells to shrink prostate and bladder cancers
- Researchers combine herpes virus with cancer vaccine to treat brain cancer in children
- UK MRC and AstraZeneca partner for translational clinical research
